Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

7 High-Yield Stock Gems for Income-Obsessed Investors

By Chris Lau, InvestorPlace Contributor

Investors seeking big payouts should consider these seven high-yield stocks from various sectors. They range from pharmaceuticals to REITs.

7 Stocks to Buy for Their Resistance to the 6.2% Monthly Inflation

By Chris Lau, InvestorPlace Contributor

These seven companies either have no exposure to inflation or have strong branding and customer loyalty, enabling them to pass higher costs.

Teledoc Stock Will Break Out with New Product Features

By Chris Lau, InvestorPlace Contributor

Teledoc’s product suite myStrength Complete and Primary 360 will enhance growth in the coming quarters and into 2023. With Teledoc's integration with Livongo's product features, the company is bound to soar high.

Why SoFI Stock Is Poised to Reach New Highs

By Chris Lau, InvestorPlace Contributor

SoFi posted strong membership growth in the last quarter that lifted its revenue, as it introduced multiple products to attract consumers.

Palantir Might Be Worth the Buy for Patient Investors

By Chris Lau, InvestorPlace Contributor

Palantir shares slipped after posting Q3 results, as investors expected more than 40% revenue growth for this year and beyond.

Load More